 GlaxoSmithKline received the bulk of the fines, being fined £37,600,757.Other companies, which produce generics, were issued fines which collectively total £7,384,146.UK public health services are likely to claim damages for being overcharged in the period where the generic versions of the drug were illegally blocked from the market, as the generics are over 70% less expensive.